- Abivax‘s lead drug candidate, obefazimod, demonstrated positive clinical trial results for ulcerative colitis, leading to a significant stock price increase.
- An analyst from BTIG set a price target of $175.00 for Abivax, indicating a potential 82% upside from its previous trading price of $96.15.
- Despite the positive data, some analysts, including Jefferies, maintain caution regarding the drug’s long-term cancer risk, even as the company’s market capitalization stands at approximately $6.30 billion.
Abivax (NASDAQ: ABVX) is a French biotechnology company focused on developing innovative treatments for inflammatory diseases. Its main drug candidate is obefazimod, which is in late-stage development for treating ulcerative colitis, a type of bowel disease. The company’s progress with this crucial drug is closely watched by investors and analysts in the pharmaceutical sector.
Julian Harrison, an analyst at BTIG, has set a price target of $175.00 for Abivax. A price target is an analyst’s projection of a stock’s future price. At the time of the rating, the stock price was at $96.15, meaning this target suggests a potential increase of about 82%, highlighting significant investment potential.
This positive outlook follows new clinical trial data on obefazimod. The company announced that the drug helped patients who did not respond to other treatments, as highlighted by Reuters. This news caused Abivax shares to rise 25%, recovering from a previous 44% drop that occurred after an earlier study showed cancer cases, demonstrating a strong market reaction to the positive news.
The latest maintenance study results further strengthen the drug’s safety profile. As reported by GlobeNewswire, the study showed that among patients who did not initially respond, 37.2% achieved clinical remission after 44 weeks. The data also showed that malignancies, or cancers, were in line with expected background rates, providing crucial insights into obefazimod’s long-term viability.
Despite the positive update, some analysts remain cautious. Jefferies analysts noted the update was “supportive” but questioned if it was enough for investors, stating the “cancer risk may be tough to discount.” Abivax has a market capitalization, or total company value, of approximately $6.30 billion, reflecting its current valuation in the biotechnology market.
